Erratum: Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia (Apoptosis (2008) 13 (1148-1161)(DOI 10.1007/s10495-008-0243-4));Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

Apoptosis

Volumn 13, Issue 9, 2008, Pages 1148-1161

  Grosjean Raillard, Jennifer ^a,b,c   Adès, Lionel ^a,b,c,d   Boehrer, Simone ^a,b,c,d   Tailler, Maximilien ^a,b,c   Fabre, Claire ^a,b,c   Braun, Thorsten ^d   De Botton, Stéphane ^b   Israel, Alain ^e   Fenaux, Pierre ^d   Kroemer, Guido ^a,b  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d AVICENNE HOSPITAL   (France)

^e INSTITUT PASTEUR   (France)

Author keywords

Acute myeloid leukemia; Flt3; IKK; NF B

Indexed keywords

2 ACYLAMINOTHIOPHENE (3,4 DI O METHYLPHENYL) 3 CARBOXAMIDE; ANTINEOPLASTIC AGENT; CD135 ANTIGEN; CD135 ANTIGEN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; SMALL INTERFERING RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CD34 SELECTION; CELL KILLING; CELL LINE; CELL MEMBRANE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENETIC EPISTASIS; HUMAN; HUMAN CELL; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RISK ASSESSMENT;

EID: 49349094497     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-015-1154-9     Document Type: Erratum

References (49)

1. Y Yamamoto H Kiyoi Y Nakano R Suzuki Y Kodera 2001 Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies Blood 97 2434 2439 10.1182/blood.V97.8.2434
2. S Yokota H Kiyoi M Nakao T Iwai S Misawa 1997 Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines Leukemia 11 1605 1609 10.1038/sj.leu.2400812
3. K Ozeki H Kiyoi Y Hirose M Iwai M Ninomiya 2004 Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia Blood 103 1901 1908 Epub 2003 Nov 1906
4. R Zheng M Levis O Piloto P Brown BR Baldwin 2004 FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells Blood 103 267 274 Epub 2003 Sep 2011
5. C Thiede C Steudel B Mohr M Schaich U Schakel 2002 Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis Blood 99 4326 4335 10.1182/blood.V99.12.4326
6. PD Kottaridis RE Gale ME Frew G Harrison SE Langabeer 2001 The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood 98 1752 1759 10.1182/blood.V98.6.1752
7. FM Abu-Duhier AC Goodeve GA Wilson MA Gari IR Peake 2000 FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group Br J Haematol 111 190 195 10.1046/j.1365-2141.2000.02317.x
8. S Takahashi H Harigae M Kaku T Sasaki JD Licht 2004 Flt3 mutation activates p21WAF1/CIP1 gene expression through the action of STAT5 Biochem Biophys Res Commun 316 85 92 10.1016/j.bbrc.2004.02.018
9. S Takahashi MJ McConnell H Harigae M Kaku T Sasaki 2004 The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT Blood 103 4650 4658 Epub 2004 Feb 4624
10. DG Gilliland JD Griffin 2002 The roles of FLT3 in hematopoiesis and leukemia Blood 100 1532 1542 10.1182/blood-2002-02-0492
11. S Horiike S Yokota M Nakao T Iwai Y Sasai 1997 Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia Leukemia 11 1442 1446 10.1038/sj.leu.2400770
12. G Bonizzi M Karin 2004 The two NF-kappaB activation pathways and their role in innate and adaptive immunity Trends Immunol 25 280 288 10.1016/j.it.2004.03.008
13. M Karin Y Yamamoto QM Wang 2004 The IKK NF-kappa B system: a treasure trove for drug development Nat Rev Drug Discov 3 17 26 10.1038/nrd1279
14. ML Guzman SJ Neering D Upchurch B Grimes DS Howard 2001 Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells Blood 98 2301 2307 10.1182/blood.V98.8.2301
15. KU Birkenkamp M Geugien H Schepers J Westra HH Lemmink 2004 Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway Leukemia 18 103 112 10.1038/sj.leu.2403145
16. P Greenberg C Cox MM LeBeau P Fenaux P Morel 1997 International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 2079 2088
17. T Braun G Carvalho A Coquelle MC Vozenin P Lepelley 2006 NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome Blood 107 1156 1165 10.1182/blood-2005-05-1989
18. FR Greten M Karin 2004 The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer Cancer Lett 206 193 199 10.1016/j.canlet. 2003.08.029
19. E Griessinger V Imbert P Lagadec N Gonthier P Dubreuil 2007 AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells Leukemia 21 877 885
20. S Takahashi H Harigae KK Ishii M Inomata T Fujiwara 2005 Over-expression of Flt3 induces NF-kappaB pathway and increases the expression of IL-6 Leuk Res 29 893 899 10.1016/j.leukres.2005.01.008
21. M Levis J Allebach KF Tse R Zheng BR Baldwin 2002 A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo Blood 99 3885 3891 10.1182/blood.V99.11.3885
22. LM Kelly JC Yu CL Boulton M Apatira J Li 2002 CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML) Cancer Cell 1 421 432 10.1016/S1535-6108(02)00070-3
23. R Grundler C Thiede C Miething C Steudel C Peschel 2003 Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor Blood 102 646 651 Epub 2003 Mar 2027
24. BD Smith M Levis M Beran F Giles H Kantarjian 2004 Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia Blood 103 3669 3676 Epub 2004 Jan 3615
25. DL Stirewalt JP Radich 2003 The role of FLT3 in haematopoietic malignancies Nat Rev Cancer 3 650 665 10.1038/nrc1169
26. W Fiedler R Mesters H Tinnefeld S Loges P Staib 2003 A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia Blood 102 2763 2767 Epub 2003 Jul 2763
27. DK Walters EP Stoffregen MC Heinrich MW Deininger BJ Druker 2005 RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518 Blood 105 2952 2954 Epub 2004 Dec 2957
28. JW Vardiman NL Harris RD Brunning 2002 The World Health Organization (WHO) classification of the myeloid neoplasms Blood 100 2292 2302 10.1182/blood-2002-04-1199
29. Z Hassan B Fadeel B Zhivotovsky E Hellstrom-Lindberg 1999 Two pathways of apoptosis induced with all-trans retinoic and etoposide in the myeloid cell line P39 Exp Hematol 27 8 1322 1329
30. C Fabre G Carvalho E Tasdemir T Braun L Ades 2007 NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia Oncogene 26 4071 4083 10.1038/sj.onc.1210187
31. M Castedo JL Perfettini G Kroemer 2002 Mitochondrial apoptosis and the peripheral benzodiazepine receptor: a novel target for viral and pharmacological manipulation J Exp Med 196 1121 1125 10.1084/jem.20021758
32. N Zamzami G Kroemer 2004 Methods to measure membrane potential and permeability transition in the mitochondria during apoptosis Methods Mol Biol 282 103 115
33. M Castedo T Hirsch SA Susin N Zamzami P Marchetti 1996 Sequential acquisition of mitochondrial and plasma membrane alterations during early lymphocyte apoptosis J Immunol 157 512 521
34. D Metivier B Dallaporta N Zamzami N Larochette SA Susin 1998 Cytofluorometric detection of mitochondrial alterations in early CD95/Fas/APO-1-triggered apoptosis of Jurkat T lymphoma cells. Comparison of seven mitochondrion-specific fluorochromes Immunol Lett 61 157 163 10.1016/S0165-2478(98)00013-3
35. Y Matsuo RA MacLeod CC Uphoff HG Drexler C Nishizaki 1997 Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23) Leukemia 11 1469 1477 10.1038/sj.leu.2400768
36. RJ Patch CA Baumann J Liu AC Gibbs H Ott 2006 Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3 Bioorg Med Chem Lett 16 3282 3286 10.1016/j.bmcl.2006.03.032
37. F Mercurio H Zhu BW Murray A Shevchenko BL Bennett 1997 IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation Science 278 860 866 10.1126/science.278.5339.860
38. R Weil K Schwamborn A Alcover C Bessia V Di Bartolo 2003 Induction of the NF-kappaB cascade by recruitment of the scaffold molecule NEMO to the T cell receptor Immunity 18 13 26 10.1016/S1074-7613(02)00506-X
39. D Boudard O Sordet C Vasselon V Revol MF Bertheas 2000 Expression and activity of caspases 1 and 3 in myelodysplastic syndromes Leukemia 14 2045 2051 10.1038/sj.leu.2401959
40. JE Parker GJ Mufti F Rasool A Mijovic S Devereux 2000 The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS Blood 96 3932 3938
41. JE Parker GJ Mufti 1998 Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes Br J Haematol 101 220 230 10.1046/j.1365-2141.1998. 00708.x
42. R Tehranchi B Fadeel AM Forsblom B Christensson J Samuelsson 2003 Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors Blood 101 1080 1086 10.1182/blood-2002-06-1774
43. H Quentmeier J Reinhardt M Zaborski HG Drexler 2003 FLT3 mutations in acute myeloid leukemia cell lines Leukemia 17 120 124 10.1038/sj.leu.2402740
44. RW Stam ML den Boer P Schneider P Nollau M Horstmann 2005 Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia Blood 106 2484 2490 10.1182/blood-2004-09-3667
45. I Lavon I Goldberg S Amit L Landsman S Jung 2000 High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-kappaB activation Nat Med 6 573 577 10.1038/75057
46. Y Fernandez M Verhaegen TP Miller JL Rush P Steiner 2005 Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications Cancer Res 65 6294 6304 10.1158/0008-5472.CAN-05-0686
47. HJ McKenna KL Stocking RE Miller K Brasel T De Smedt 2000 Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells Blood 95 3489 3497
48. BD Lee S Sevcikova SC Kogan 2006 Dual treatment with FLT3 inhibitor SU11657 and doxorubicin increases survival of leukemic mice Leuk Res 31 8 1131 1134
49. AM O'Farrell TJ Abrams HA Yuen TJ Ngai SG Louie 2003 SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Blood 101 3597 3605 10.1182/blood-2002-07-2307